1. Pirofsky B. The hemolytic anaemias — historical review and classification // In: Pirofsky B, ed. Autoimmunisation and the Autoimmune Hemolytic Anaemias. — Baltimore, MD: Williams & Wilkins, 1969; pp. 3—20.
2. Руководство по гематологии. Под ред. Воробьева А. И. — М.: Ньюдиамед, 2005.
3. Ozsoylu S. High dose intravenous methylprednisolone (HIVMP) in gematologic disorders. Hematol Rev 1990; 4:197-207.
4. Meyer O, Stahl D, Beckhove P et al. Pulsed high-dose dexamethasone in chronic autoimmune haemolytic anaemia of warm type. Br J Haematol 1997; 98:860—862.
5. Hersh J, Dacie JV. Persistent post-splenectomy thrombocytosis and thrombo-embolism: a consequence of continuing anaemia. Br J Haematol 1966; 12:44—53.
6. Moyo VM, Smith D, Brodsky I et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 2002; 100:704—706.
7. Emilia G, Messora C, Longo G, Bertesi M. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol 1996; 93:341—344.
8. Dundar S, Ozdemir O, Ozcebe O. Cyclosporin in steroid-resistant auto-immune haemolytic anaemia. Acta Haematol 1991; 86:200—202.
9. Rackoff WR, Manno CS. Treatment of refractory Evans syndrome with alternate-day cyclosporine and prednisolone. Am J Pediatr Hematol Oncol 1994; 16:156—159.
10. Ahn YS. Efficacy of danazol in hematologic disorders. Acta Haematol 1990; 84:122—129.
11. Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol 1993; 83:343—345.
12. Hill Q, Stamps R, Massey E et al.tThe diagnosis and management of primary autoimmune haemolitic anamia Br J Haematol 2017; 176:395—411.
13. Reynaud Q, Durieu I, Dutertre M et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev 2015; 14:304—313.
14. Barcellini W, Zaja F, Zaninoni A et al. Sustainedresponseto low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Hematology 2013; 91:546—551.
15. Bigrens H, Frederiksen H, Hasselbalch HC. A phase III randomize trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anemia. Br J Haematol 2013; 163:393—399.
16. Maung SW, Leahy M, O'Leary HM et al. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. Br J Haematol 2013; 163:118—122.
17. Penalver F, Alvarez- A, Diez-Martin JL. Rituximab is an effective and safe therapeutic alnernative in adults with refractory and severe autoimmune hemolytic anemia. Multi-institutional Retrospective Study on the use of rituximab in refractory AIHA. Ann Hematol 2010; 89:1073—1080.
18. Berentsen S, Ulvestad E. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 course of therapy in 27 patients. Blood 2004: 103:2925—2928.
19. Packman CH. Hemolytic anemia due to warm autoantibodies. Blood Rev 2008; 22:17—31.
20. Zeerleder S. Autoimmune haemolytic anaemia — a practical guide to cope with a diagnostic and therapeutic challenge. Neth J Med 2011; 69:177—184.
21. Petz LD. Diagnostic complexities in autoimmune hemolytic anemias. Transfution. 2009; 49: 202—203.
22. Barcellini W. New insights in the pathogenesis of AIHA. Transfus Med Hemother 2015; 42:287—293.
23. Kalfa TA. Warm antibody autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Progr 2016; 2:690—697.
24. Bass GF, Tuscano ET. Diagnosis and classification of autoimmune hemolytic anemia. Autoiimmune Rev 2014; 13:560—564.
25. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemia. Haematologica 2014$ 99:1547—1554.